Matt Kaeberlein: A Solution to the Peptide Problem
Peer-Reviewed Research
Key Takeaways
- Unregulated peptides face exploding demand but lack safety/efficacy data due to missing clinical trials.
- NIH or Arpa-H should fund rigorous trials for 15-20 common peptides—costing only a fraction of their budgets.
- Coordinate with FDA to create a clear regulatory path instead of relying on opinions or anecdotal evidence.
Notable Quotes
“Instead of guessing, we’d know.”
Bottom Line
Advocate for NIH/Arpa-H-funded clinical trials on unregulated peptides to replace speculation with evidence-based regulation.
Explore More
- Matt Kaeberlein’s Full Protocol — supplements, dosages, and daily routine
- Compare All Protocols — side-by-side protocols
Watch the Full Video
Medical Disclaimer
This article is for informational purposes only and does not constitute medical advice. The research summaries presented here are based on published studies and should not be used as a substitute for professional medical consultation. Always consult a qualified healthcare provider before making any changes to your health regimen.
Peer-reviewed health research, simplified. Early access findings, clinical trial alerts & regulatory news — delivered weekly.
No spam. Unsubscribe anytime. Powered by Beehiiv.
Related Research
- Max Lugavere: The Science of Confidence, Self-Trust & the Power of Action - Shadé Zahrai
- Michael Greger: Live Q&A with Dr. Greger
- Rhonda Patrick: The supplement that powers the New England Patriots
- Gabrielle Lyon: How to Stay Calm in a Crisis and Why Detachment Is a Trainable Skill - Jamie Cochran | GLS #209
From Our Research Network
Daily longevity researchZone2 Training
Exercise protocolsSleep Science
Sleep optimization
Part of the Evidence-Based Research Network